Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Published in: Blood cancer journal
Access to document
10.1038/s41408-023-00903-w
document
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL...
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland
Zoonotic Transmission of Vaccine-Derived Bordetella bronchiseptica.
Published in: Open Forum Infectious Diseases
Access to document
10.1093/ofid/ofad421
document
We describe a unique case of a 43-year-old-female with a Bordetella bronchiseptica infection caused by zoonotic transmission following vaccination of her dog. With this report, we want to raise awareness of potential zoonotic transmission of live attenuated vaccines from animals to patients with impaired immunity.
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
Published in: Blood cancer journal
Access to document
10.1038/s41408-023-00854-2
document
Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP (R2CHOP) is well-tolerated and yields similar complete metabolic remission rates as more intensive chemotherapy regimens in literature. In parallel with this single-arm interventional trial, a prospective observational screening cohort (HOVON-900) was open in which we identified all newly diagnosed MYC-R DLBCL patients in the Netherlands. Eligible patients from the observational cohort that were not included in the interventional...
A. Vera de Jonge, Erik van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G.G.M. Rutten, Rogier Mous, Joost S.P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry Koene, Marie José Kersten, Daphne de Jong, Martine E.D. Chamuleau
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Published in: The Lancet Haematology
Access to document
10.1016/S2352-3026(23)00030-3
Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list...
Cristina Nanni, Carsten Kobe, Bettina Baeßler, Christian Baues, Ronald Boellaard, Peter Borchmann, Andreas Buck, Irène Buvat, Björn Chapuy, Bruce D. Cheson, Robert Chrzan, Ann Segolene Cottereau, Ulrich Dührsen, Live Eikenes, Martin Hutchings, Wojciech Jurczak, Françoise Kraeber-Bodéré, Egesta Lopci, Stefano Luminari, Steven MacLennanN. George Mikhaeel, Marcel Nijland, Paula Rodríguez-Otero, Giorgio Treglia, Nadia Withofs, Elena Zamagni, Pier Luigi Zinzani, Josée M. Zijlstra, Ken Herrmann, Jolanta Kunikowska
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome
Published in: Rheumatology
Access to document
10.1093/rheumatology/kead071
OBJECTIVES: To assess the usefulness of FDG-PET/CT 1) to discriminate between pSS patients with and without lymphomas and 2) to evaluate systemic disease activity in pSS. METHODS: ACR-EULAR-positive pSS patients who underwent FDG-PET/CT were included. Scans were visually evaluated and quantitative analysis was performed by measuring standardized uptake values (SUV) of salivary and lacrimal glands and systemic regions. ROC analyses were performed to find SUV cut-off values to discriminate between lymphoma and non-lymphoma. RESULTS: 26 of the 70 included patients were diagnosed with a pSS-associated lymphoma, mostly of...